Skip to main content
Home
Online First
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Online First
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
John Malamakal, PharmD, MS, BCPS, BCOP
Authored Items
Enzalutamide Administration for a Nonhemodialysis Patient with Stage 4 Chronic Kidney Disease and Nonmetastatic Castration-Resistant Prostate Cancer
So Jung Uhm, PharmD
,
John Malamakal, PharmD, MS, BCPS, BCOP
JHOP - October 2020 Vol 10, No 5
in
Case Reports
,
Kidney Disease
,
Dose Escalation/Reduction
,
Prostate Cancer
Impact of Weight-Based Melphalan Dosing Strategies in Autologous Hematopoietic Stem-Cell Transplant for Multiple Myeloma
Erin K. Yeung, PharmD, BCPS
,
John Malamakal, PharmD, MS, BCPS, BCOP
JHOP - June 2020 Vol 10, No 3
in
Original Article
,
Dose Escalation/Reduction
,
Multiple Myeloma
,
Transplant
Last modified: June 24, 2020